As shown in Fig. 3e, there was no observable effect on cell viability following combinational treatment suggesting that PF treatment is selective for BCR-ABL-expressing CML cells. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.